Researchers review how lorlatinib works in everyday chinese lung cancer patients
NCT ID NCT07556549
First seen May 04, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study looks back at medical records of 50 Chinese adults with ALK-positive advanced non-small cell lung cancer who started treatment with the drug lorlatinib. The goal is to understand patient characteristics and how the drug is used in real-world settings. No new treatments or visits are involved—only existing data is reviewed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Beijing, China
Conditions
Explore the condition pages connected to this study.